Cargando…
LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders
Peroxisomes are central hubs for cell metabolism and their dysfunction is linked to devastating human disorders, such as peroxisomal biogenesis disorders and single peroxisomal enzyme/protein deficiencies. For decades, biochemical diagnostics have been carried out using classical markers such as ver...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226985/ https://www.ncbi.nlm.nih.gov/pubmed/34072483 http://dx.doi.org/10.3390/metabo11060347 |
_version_ | 1783712417601028096 |
---|---|
author | Klemp, Henry Gerd Kettwig, Matthias Streit, Frank Gärtner, Jutta Rosewich, Hendrik Krätzner, Ralph |
author_facet | Klemp, Henry Gerd Kettwig, Matthias Streit, Frank Gärtner, Jutta Rosewich, Hendrik Krätzner, Ralph |
author_sort | Klemp, Henry Gerd |
collection | PubMed |
description | Peroxisomes are central hubs for cell metabolism and their dysfunction is linked to devastating human disorders, such as peroxisomal biogenesis disorders and single peroxisomal enzyme/protein deficiencies. For decades, biochemical diagnostics have been carried out using classical markers such as very long-chain fatty acids (VLCFA), which can be inconspicuous in milder and atypical cases. Holistic metabolomics studies revealed several potentially new biomarkers for peroxisomal disorders for advanced laboratory diagnostics including atypical cases. However, establishing these new markers is a major challenge in routine diagnostic laboratories. We therefore investigated whether the commercially available AbsoluteIDQ p180 kit (Biocrates Lifesciences), which utilizes flow injection and liquid chromatography mass spectrometry, may be used to reproduce some key results from previous global metabolomics studies. We applied it to serum samples from patients with mutations in peroxisomal target genes PEX1, ABCD1, and the HSD17B4 gene. Here we found various changes in sphingomyelins and lysophosphatidylcholines. In conclusion, this kit can be used to carry out extended diagnostics for peroxisomal disorders in routine laboratories, even without access to a metabolomics unit. |
format | Online Article Text |
id | pubmed-8226985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82269852021-06-26 LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders Klemp, Henry Gerd Kettwig, Matthias Streit, Frank Gärtner, Jutta Rosewich, Hendrik Krätzner, Ralph Metabolites Article Peroxisomes are central hubs for cell metabolism and their dysfunction is linked to devastating human disorders, such as peroxisomal biogenesis disorders and single peroxisomal enzyme/protein deficiencies. For decades, biochemical diagnostics have been carried out using classical markers such as very long-chain fatty acids (VLCFA), which can be inconspicuous in milder and atypical cases. Holistic metabolomics studies revealed several potentially new biomarkers for peroxisomal disorders for advanced laboratory diagnostics including atypical cases. However, establishing these new markers is a major challenge in routine diagnostic laboratories. We therefore investigated whether the commercially available AbsoluteIDQ p180 kit (Biocrates Lifesciences), which utilizes flow injection and liquid chromatography mass spectrometry, may be used to reproduce some key results from previous global metabolomics studies. We applied it to serum samples from patients with mutations in peroxisomal target genes PEX1, ABCD1, and the HSD17B4 gene. Here we found various changes in sphingomyelins and lysophosphatidylcholines. In conclusion, this kit can be used to carry out extended diagnostics for peroxisomal disorders in routine laboratories, even without access to a metabolomics unit. MDPI 2021-05-29 /pmc/articles/PMC8226985/ /pubmed/34072483 http://dx.doi.org/10.3390/metabo11060347 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Klemp, Henry Gerd Kettwig, Matthias Streit, Frank Gärtner, Jutta Rosewich, Hendrik Krätzner, Ralph LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders |
title | LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders |
title_full | LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders |
title_fullStr | LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders |
title_full_unstemmed | LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders |
title_short | LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders |
title_sort | lc-ms based platform simplifies access to metabolomics for peroxisomal disorders |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226985/ https://www.ncbi.nlm.nih.gov/pubmed/34072483 http://dx.doi.org/10.3390/metabo11060347 |
work_keys_str_mv | AT klemphenrygerd lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders AT kettwigmatthias lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders AT streitfrank lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders AT gartnerjutta lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders AT rosewichhendrik lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders AT kratznerralph lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders |